{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"1.15","upperLimit":"NA","value":"3.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the time from starting study treatment to disease progression or death from any cause. The International Myeloma Working Group (IMWG) criteria defines progressive disease (PD) as at least 25% increase from lowest response value of any of the following:\n\n* Serum M-component (absolute increase must be at least 0.5 g/dL)\n* Urine M-component (absolute increase must be at least 200 mg/24 h)\n* If serum and urine M-protein unmeasurable, absolute increase in free light chain (FLC) must be \\>10 mg/dL. If FLC levels also unmeasurable, absolute increase in bone marrow plasma cell percentage must be at least 10%.\n* Definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"\\- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.\n\n* Oral:\n\n  * Ixazomib given weekly on days 1, 8, 15\n  * Dexamethasone given weekly during cycle\n* Infused:\n\n  * Nivolumab given once per cycle\n  * Cyclophosphamide given on days 1, 8, 15 during cycle\n\nNivolumab: Given intravenously once per cycle\n\nIxazomib: Given orally on days 1, 8, 15.\n\nDexamethasone: Given orally on days 1, 8, 15, 22\n\nCyclophosphamide: Given intravenously on days 1, 8, 15.","id":"OG000","title":"Nivolumab and Ixazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}